Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.
about
Conjugate vaccines for preventing meningococcal C meningitis and septicaemiaConjugate vaccines for preventing meningococcal C meningitis and septicaemiaProspects for vaccine prevention of meningococcal infectionBaseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccineDissecting the indirect effects caused by vaccines into the basic elementsThe impact of new vaccine introduction on immunization and health systems: a review of the published literatureMeningococcal carriage and disease--population biology and evolutionEvaluation of swabbing methods for estimating the prevalence of bacterial carriage in the upper respiratory tract: a cross sectional studyAn evaluation of emerging vaccines for childhood meningococcal diseaseHistory of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention.Meningococcal conjugate vaccines.Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana.Invasive meningococcal disease epidemiology and control measures: a framework for evaluationUpdated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityA Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine.Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccinesProtein carriers of conjugate vaccines: characteristics, development, and clinical trials.Vaccine herd effect.Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis.Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.A study of physico-chemical interactions between Haemophilus influenzae type b and meningococcus group C conjugate vaccinesEarly appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvacInterference and Sensitivity Analysis.Time is (still) of the essence: quantifying the impact of emergency meningitis vaccination response in Katsina State, Nigeria.Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics.From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease.Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera.Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.Meningococcal disease serogroup C.Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research.Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccinesMeningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
P2860
Q24235722-A1A41A02-6F0A-4E7F-A622-93B6CC393F0AQ24244951-6A9C8DD6-0ECC-4D42-913D-58853CCBB7E7Q24537338-4F89F3D8-521A-4237-899F-628AB03AA09AQ24629949-A9A7934D-B59E-4318-99FD-048BB833CD74Q26799527-AE27CFFC-74DA-49CD-8BC4-0E2175FCED8CQ27009450-C9A82FC6-14D7-4CC9-9FF7-9476A86445BFQ28246008-9EDBCB83-C29A-47E5-A4FA-92E21C6447A4Q28652846-EF9BD3B2-F365-40B7-B748-72D1F7215D9EQ28741833-A9743248-DA6D-401A-8A6A-19E09D13C20BQ30249427-34A7E9FD-44A6-4A98-84BF-33DBADA8A097Q30341333-0A1A18E0-4F81-42E8-9BDE-77F2E1B6AE80Q33280136-D0C34C41-05CB-40CA-8A05-7B6752EE4436Q33289528-A563671B-D580-42FD-87E1-73E20A4277ACQ33825722-F2485DD0-5C0C-4C9F-B680-FEDF9DC3EC47Q33939014-2F16BCA4-F0CF-4845-BE80-2D6B9F1CEE9BQ34042082-4CB4766F-AE76-42ED-B517-1178B51DEC16Q34170021-24B9C065-A62E-425A-90F7-BBAA10C322AEQ34186752-51C1B4D1-C18A-4C32-878F-047C730F3662Q34231871-6C478D64-6AC6-4A3A-AEA0-891A34B8058BQ34346578-19841A08-8498-400B-85BD-6E5041787CDDQ34627685-4600943C-8A8F-43B1-918A-902A74D196FEQ34707962-D6DD90E3-81BE-4B37-B8D6-4D9B48E3754DQ34738958-65A369B1-7328-477A-B2D4-81D5163A533CQ34780775-A3A33B99-1055-4C29-B380-D6E97DBE573CQ34975007-3E8F28DE-EB8E-4612-9D51-C028AD86B363Q34975624-085196C2-4139-439C-895B-5FE9F895C870Q34990758-1ABD876D-EC22-4156-A819-8EA283D345E9Q35029246-ECD0A6F2-1F49-4E40-8CAC-9A4E1548B2EFQ35048994-813F4EC9-5141-43BB-B2B9-0D1990B1EF74Q35453441-D5286680-21EF-4768-9BA8-B342E3A5CBB0Q35542142-F85F9BA3-90BD-480B-A009-59120466DEC4Q35783606-2A6C08A2-8969-4667-A289-6DF0FA6A83DBQ35799561-7097909F-11F9-45E3-83B8-2FE2898AEC03Q35805284-DE53205D-9759-41DA-8A5D-16B745C2ECD4Q35832179-BE4B7207-B985-46DC-B2E9-0F191282C287Q35887266-F219572A-285E-4277-88D7-FC8B411CF9FCQ35887617-89955BEE-552F-4DA4-9DF8-C0B81690F108Q35901353-5BB4EFBE-85BC-441A-A2BE-23D0EB0F1449Q36065267-4BB6EE27-B462-4F2B-A99D-E2399FAD02BCQ36154043-7387C5E5-7C01-4630-AE6D-6532D00A6729
P2860
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Herd immunity from meningococc ...... in England: database analysis.
@ast
Herd immunity from meningococc ...... in England: database analysis.
@en
Herd immunity from meningococc ...... in England: database analysis.
@nl
type
label
Herd immunity from meningococc ...... in England: database analysis.
@ast
Herd immunity from meningococc ...... in England: database analysis.
@en
Herd immunity from meningococc ...... in England: database analysis.
@nl
prefLabel
Herd immunity from meningococc ...... in England: database analysis.
@ast
Herd immunity from meningococc ...... in England: database analysis.
@en
Herd immunity from meningococc ...... in England: database analysis.
@nl
P2093
P2860
P356
P1433
P1476
Herd immunity from meningococc ...... in England: database analysis.
@en
P2093
Caroline L Trotter
Edward B Kaczmarski
Elizabeth Miller
Mary E Ramsay
Nick J Andrews
P2860
P304
P356
10.1136/BMJ.326.7385.365
P407
P577
2003-02-01T00:00:00Z